Wolfe Research stays Outperform on Johnson & Johnson (JNJ): focus shifts to upcoming h2h trial data
Tweet Send to a Friend
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $260.00 price target on Johnson & Johnson (NYSE: JNJ)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
